155 related articles for article (PubMed ID: 23371453)
1. Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis.
Kurihara Y; Hitomi S; Oishi T; Kondo T; Ebihara T; Funayama Y; Kawakami Y
J Infect Chemother; 2013 Oct; 19(5):799-805. PubMed ID: 23371453
[TBL] [Abstract][Full Text] [Related]
2. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.
Ahn JY; Ann HW; Jeon Y; Ahn MY; Oh DH; Kim YC; Kim EJ; Song JE; Jung IY; Kim MH; Jeong W; Ku NS; Jeong SJ; Choi JY; Yong D; Song YG; Kim JM
BMC Infect Dis; 2017 May; 17(1):327. PubMed ID: 28468622
[TBL] [Abstract][Full Text] [Related]
3. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
[TBL] [Abstract][Full Text] [Related]
4. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
5. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
[TBL] [Abstract][Full Text] [Related]
6. Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia.
Lee CC; Lee CH; Hong MY; Hsieh CC; Tang HJ; Ko WC
J Microbiol Immunol Infect; 2018 Aug; 51(4):519-526. PubMed ID: 28698042
[TBL] [Abstract][Full Text] [Related]
7. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
[TBL] [Abstract][Full Text] [Related]
8. Distribution and antimicrobial susceptibility profile of extended-spectrum β-lactamase-producing Proteus mirabilis strains recently isolated in Japan.
Kanayama A; Kobayashi I; Shibuya K
Int J Antimicrob Agents; 2015 Feb; 45(2):113-8. PubMed ID: 25182712
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia.
Sohn KM; Kang CI; Joo EJ; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
Korean J Intern Med; 2011 Mar; 26(1):89-93. PubMed ID: 21437168
[TBL] [Abstract][Full Text] [Related]
10. High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis strains in southern Croatia.
Tonkić M; Mohar B; Šiško-Kraljević K; Meško-Meglič K; Goić-Barišić I; Novak A; Kovačić A; Punda-Polić V
J Med Microbiol; 2010 Oct; 59(Pt 10):1185-1190. PubMed ID: 20558587
[TBL] [Abstract][Full Text] [Related]
11. [The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].
Kwiecińska-Piróg J; Bogiel T; Gospodarek E
Przegl Epidemiol; 2010; 64(3):395-8. PubMed ID: 20976952
[TBL] [Abstract][Full Text] [Related]
12. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
13. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
[TBL] [Abstract][Full Text] [Related]
14. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
15. Outbreak caused by Proteus mirabilis isolates producing weakly expressed TEM-derived extended-spectrum β-lactamase in spinal cord injury patients with recurrent bacteriuria.
Cremet L; Bemer P; Rome J; Juvin ME; Navas D; Bourigault C; Guillouzouic A; Caroff N; Lepelletier D; Asseray N; Perrouin-Verbe B; Corvec S
Scand J Infect Dis; 2011 Dec; 43(11-12):957-61. PubMed ID: 21888562
[TBL] [Abstract][Full Text] [Related]
16. VEB-6 extended-spectrum beta-lactamase-producing Proteus mirabilis from Sultanate of Oman.
Potron A; Poirel L; Elhag K; Al Yaqoubi F; Nordmann P
Int J Antimicrob Agents; 2009 Nov; 34(5):493-4. PubMed ID: 19525094
[No Abstract] [Full Text] [Related]
17. Bloodstream infections caused by multi-drug resistant Proteus mirabilis: Epidemiology, risk factors and impact of multi-drug resistance.
Korytny A; Riesenberg K; Saidel-Odes L; Schlaeffer F; Borer A
Infect Dis (Lond); 2016; 48(6):428-31. PubMed ID: 26763474
[TBL] [Abstract][Full Text] [Related]
18. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
[TBL] [Abstract][Full Text] [Related]
19. Regional Spread of CTX-M-2-Producing Proteus mirabilis with the Identical Genetic Structure in Japan.
Kato K; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S
Microb Drug Resist; 2017 Jul; 23(5):590-595. PubMed ID: 27834610
[TBL] [Abstract][Full Text] [Related]
20. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
